AQST News and Press, Aquestive Therapeutics Inc. From 02/25/22

Aquestive Therapeutics (NASDAQ:AQST) is trading ~6% higher in the premarket Friday after the commercial-stage pharmaceutical company announced positive topline data from its Part 1 of the EPIPHAST study for AQST-109 epinephrine oral film. In the randomized open-label trial involving...

First and only orally delivered epinephrine product candidate AQST-109 continues to show rapid absorption with a median time to peak concentration (Tmax) of 13.5 minutes AQST-109 was safe and well tolerated Part 2 of the EPIPHAST trial commenced WAR...

Aquestive Therapeutics (NASDAQ:AQST) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application (IND) for AQST-109 epinephrine oral film to enter clinical trial. The company intends to explore AQST-109, an epinephrine prodrug used as a sublingu...

WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced the opening...

Aquestive Therapeutics made several advancements last year that have set the stage for a potentially transformative year in 2022. Unfortunately, the share price ended the year on a sour note. The FDA informed the company they will not be ready to take action on their PDUFA date. AQST&...

WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company improving and advancing medicines to solve patients’ problems with current standards of care in order to better their lives with transformative products, announced to...

WARREN, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the manageme...

Aquestive Therapeutics (NASDAQ: AQST) was one of the steeper decliners among biotech stocks Tuesday. The company's shares plummeted more than 29% on a rather discouraging piece of news about one of its top drug candidates. Late Monday night, Aquestive disclosed that it had recei...

Gainers: Reliance Global Group (NASDAQ:RELI) +82%. Biofrontera (NASDAQ:BFRI) +49%. Jaguar Health (NASDAQ:JAGX) +43%. IsoPlexis (NASDAQ:ISO) +31%. Aridis Pharmaceuticals (NASDAQ:ARDS) +28%. Petros Pharmaceuticals (NASDAQ:PTPI) +30%. Eqonex (NASDAQ:EQOS) +26%. Quantum-Si incorporated (NASDAQ:QS...

Aquestive Therapeutics (NASDAQ:AQST) drops 32.8% premarket after receiving FDA notification regarding the review of the New Drug Application (NDA) for Libervant (diazepam) Buccal Film for the treatment of breakthrough seizures and seizure clusters. The notice stated, "the Agency is ...